In conclusion, liraglutide improves hepatic thyroid hormone resistance in T2DM with NAFLD, and restoration of impaired TRβ expression in NAFLD is a potential mechanism involved in the process of liraglutide therapy. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatotic liver disease.